Skip to main navigation menu Skip to main content Skip to site footer

Original article

Vol. 154 No. 11 (2024)

Safety of oral immunotherapy for cashew nut and peanut allergy in children – a retrospective single-centre study

DOI
https://doi.org/10.57187/s.3691
Cite this as:
Swiss Med Wkly. 2024;154:3691
Published
20.11.2024

Summary

AIM OF THE STUDY: Oral immunotherapy (OIT) is increasingly used for the treatment of childhood food allergies, with limited data available on cashew nut OIT. This real-life study investigated the safety and feasibility of cashew nut OIT, comparing it with peanut OIT, with a focus on the up-dosing process.

METHODS: We analysed cashew nut (n = 24) and peanut (n = 38) OIT cases with treatment initiated between 2018 and 2022 at the University Childrenʼs Hospital Basel. All patients who commenced therapy within this time frame were enrolled without prior selection. Two different starting protocols were used. Within the up-dosing protocol, the nut intake was incrementally increased by 20–30% every 2 weeks until reaching a maintenance dose of 1 g of nut protein. After consuming the maintenance dose regularly for 18–24 months, a second oral food challenge was performed. Patients who passed this challenge were considered desensitised. The safety of the therapy was evaluated based on the severity of adverse reactions during the up-dosing phase. Symptom severity was evaluated using the validated ordinal food allergy severity scale (o-FASS-5).

RESULTS: Over the study period, 33% of cashew nut-allergic and 63% of peanut-allergic patients experienced mild to moderate allergic reactions. Severe allergic reactions occurred in five peanut-allergic children with high baseline allergen-specific IgE levels. Six patients with peanut, and none with cashew nut OIT, discontinued the therapy due to adverse reactions. The mean duration to reach the maintenance phase was longer for children with asthma or another food allergy. Among children who already underwent the second oral food challenge, desensitisation was achieved in 91% (11 out of 12) of cashew nut- and 73% (11 out of 15) of peanut-allergic patients.

CONCLUSION: Cashew nut OIT had a low severity of adverse reactions and was generally well-tolerated. However, patient characteristics influenced side effect risk and treatment duration, emphasising the need for individualised OIT strategies.

References

  1. McWilliam V, Koplin J, Lodge C, Tang M, Dharmage S, Allen K. The Prevalence of Tree Nut Allergy: A Systematic Review. Curr Allergy Asthma Rep. 2015 Sep;15(9):54. doi: https://doi.org/10.1007/s11882-015-0555-8 DOI: https://doi.org/10.1007/s11882-015-0555-8
  2. Mendes C, Costa J, Vicente AA, Oliveira MB, Mafra I. Cashew Nut Allergy: Clinical Relevance and Allergen Characterisation. Clin Rev Allergy Immunol. 2019 Aug;57(1):1–22. doi: https://doi.org/10.1007/s12016-016-8580-5 DOI: https://doi.org/10.1007/s12016-016-8580-5
  3. Elizur A, Appel MY, Nachshon L, Levy MB, Epstein-Rigbi N, Golobov K, et al. NUT Co Reactivity - ACquiring Knowledge for Elimination Recommendations (NUT CRACKER) study. Allergy. 2018 Mar;73(3):593–601. doi: https://doi.org/10.1111/all.13353 DOI: https://doi.org/10.1111/all.13353
  4. Grabenhenrich LB, Dölle S, Moneret-Vautrin A, Köhli A, Lange L, Spindler T, et al. Anaphylaxis in children and adolescents: The European Anaphylaxis Registry. J Allergy Clin Immunol. 2016 Apr;137(4):1128–1137.e1. doi: https://doi.org/10.1016/j.jaci.2015.11.015 DOI: https://doi.org/10.1016/j.jaci.2015.11.015
  5. Clark AT, Anagnostou K, Ewan PW. Cashew nut causes more severe reactions than peanut: case-matched comparison in 141 children. Allergy. 2007 Aug;62(8):913–6. doi: https://doi.org/10.1111/j.1398-9995.2007.01447.x DOI: https://doi.org/10.1111/j.1398-9995.2007.01447.x
  6. Sicherer SH, Muñoz-Furlong A, Godbold JH, Sampson HA. US prevalence of self-reported peanut, tree nut, and sesame allergy: 11-year follow-up. J Allergy Clin Immunol. 2010 Jun;125(6):1322–6. doi: https://doi.org/10.1016/j.jaci.2010.03.029 DOI: https://doi.org/10.1016/j.jaci.2010.03.029
  7. Brough HA, Caubet JC, Mazon A, Haddad D, Bergmann MM, Wassenberg J, et al. Defining challenge-proven coexistent nut and sesame seed allergy: A prospective multicenter European study. J Allergy Clin Immunol. 2020 Apr;145(4):1231–9. doi: https://doi.org/10.1016/j.jaci.2019.09.036 DOI: https://doi.org/10.1016/j.jaci.2019.09.036
  8. Dölle-Bierke S, Höfer V, Francuzik W, Näher AF, Bilo MB, Cichocka-Jarosz E, et al. Food-Induced Anaphylaxis: Data From the European Anaphylaxis Registry. J Allergy Clin Immunol Pract. 2023 Jul;11(7):2069–2079.e7. doi: https://doi.org/10.1016/j.jaip.2023.03.026 DOI: https://doi.org/10.1016/j.jaip.2023.03.026
  9. Fleischer DM, Conover-Walker MK, Matsui EC, Wood RA. The natural history of tree nut allergy. J Allergy Clin Immunol. 2005 Nov;116(5):1087–93. doi: https://doi.org/10.1016/j.jaci.2005.09.002 DOI: https://doi.org/10.1016/j.jaci.2005.09.002
  10. Peters RL, Guarnieri I, Tang ML, Lowe AJ, Dharmage SC, Perrett KP, et al. The natural history of peanut and egg allergy in children up to age 6 years in the HealthNuts population-based longitudinal study. J Allergy Clin Immunol. 2022 Sep;150(3):657–665.e13. doi: https://doi.org/10.1016/j.jaci.2022.04.008 DOI: https://doi.org/10.1016/j.jaci.2022.04.008
  11. Baumert JL, Taylor SL, Koppelman SJ. Quantitative Assessment of the Safety Benefits Associated with Increasing Clinical Peanut Thresholds Through Immunotherapy. J Allergy Clin Immunol Pract. 2018;6(2):457–465.e4. doi: https://doi.org/10.1016/j.jaip.2017.05.006 DOI: https://doi.org/10.1016/j.jaip.2017.05.006
  12. Vickery BP, Vereda A, Casale TB, Beyer K, du Toit G, Hourihane JO, et al.; PALISADE Group of Clinical Investigators. AR101 Oral Immunotherapy for Peanut Allergy. N Engl J Med. 2018 Nov;379(21):1991–2001. doi: https://doi.org/10.1056/NEJMoa1812856 DOI: https://doi.org/10.1056/NEJMoa1812856
  13. de Silva D, Rodríguez Del Río P, de Jong NW, Khaleva E, Singh C, Nowak-Wegrzyn A, et al.; GA2LEN Food Allergy Guidelines Group. Allergen immunotherapy and/or biologicals for IgE-mediated food allergy: A systematic review and meta-analysis. Allergy. 2022 Jun;77(6):1852–62. doi: https://doi.org/10.1111/all.15211 DOI: https://doi.org/10.1111/all.15211
  14. Loke P, Hsiao KC, Lozinsky A, et al. Probiotic and Peanut OIT leads to long-lasting sustained unresponsiveness and quality-of-life improvement in peanut-allergic children. Authorea. July 31, 2021. DOI: 10.22541/au.162769428.85138587/v1 DOI: https://doi.org/10.22541/au.162769428.85138587/v1
  15. Jones SM, Kim EH, Nadeau KC, Nowak-Wegrzyn A, Wood RA, Sampson HA, et al.; Immune Tolerance Network. Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study. Lancet. 2022 Jan;399(10322):359–71. doi: https://doi.org/10.1016/S0140-6736(21)02390-4 DOI: https://doi.org/10.1016/S0140-6736(21)02390-4
  16. Pajno GB, Fernandez-Rivas M, Arasi S, Roberts G, Akdis CA, Alvaro-Lozano M, et al.; EAACI Allergen Immunotherapy Guidelines Group. EAACI Guidelines on allergen immunotherapy: IgE-mediated food allergy. Allergy. 2018 Apr;73(4):799–815. doi: https://doi.org/10.1111/all.13319 DOI: https://doi.org/10.1111/all.13319
  17. Vickery BP, Berglund JP, Burk CM, Fine JP, Kim EH, Kim JI, et al. Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective. J Allergy Clin Immunol. 2017 Jan;139(1):173–181.e8. doi: https://doi.org/10.1016/j.jaci.2016.05.027 DOI: https://doi.org/10.1016/j.jaci.2016.05.027
  18. Soller L, Abrams EM, Carr S, Kapur S, Rex GA, Leo S, et al. First Real-World Safety Analysis of Preschool Peanut Oral Immunotherapy. J Allergy Clin Immunol Pract. 2019;7(8):2759–2767.e5. doi: https://doi.org/10.1016/j.jaip.2019.04.010 DOI: https://doi.org/10.1016/j.jaip.2019.04.010
  19. Chu DK, Wood RA, French S, Fiocchi A, Jordana M, Waserman S, et al. Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety. Lancet. 2019 Jun;393(10187):2222–32. doi: https://doi.org/10.1016/S0140-6736(19)30420-9 DOI: https://doi.org/10.1016/S0140-6736(19)30420-9
  20. Elizur A, Appel MY, Nachshon L, Levy MB, Epstein-Rigbi N, Koren Y, et al. Cashew oral immunotherapy for desensitizing cashew-pistachio allergy (NUT CRACKER study). Allergy. 2022 Jun;77(6):1863–72. doi: https://doi.org/10.1111/all.15212 DOI: https://doi.org/10.1111/all.15212
  21. Erdle SC, Cook VE, Cameron SB, Yeung J, Kapur S, McHenry M, et al. Real-World Safety Analysis of Preschool Tree Nut Oral Immunotherapy. J Allergy Clin Immunol Pract. 2023 Apr;11(4):1177–83. doi: https://doi.org/10.1016/j.jaip.2023.01.031 DOI: https://doi.org/10.1016/j.jaip.2023.01.031
  22. Sampson HA, Gerth van Wijk R, Bindslev-Jensen C, Sicherer S, Teuber SS, Burks AW, et al. Standardizing double-blind, placebo-controlled oral food challenges: American Academy of Allergy, Asthma & Immunology-European Academy of Allergy and Clinical Immunology PRACTALL consensus report. J Allergy Clin Immunol. 2012 Dec;130(6):1260–74. doi: https://doi.org/10.1016/j.jaci.2012.10.017 DOI: https://doi.org/10.1016/j.jaci.2012.10.017
  23. Varshney P, Jones SM, Scurlock AM, Perry TT, Kemper A, Steele P, et al. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J Allergy Clin Immunol. 2011 Mar;127(3):654–60. doi: https://doi.org/10.1016/j.jaci.2010.12.1111 DOI: https://doi.org/10.1016/j.jaci.2010.12.1111
  24. Tirumalasetty J, Barshow S, Kost L, Morales L, Sharma R, Lazarte C, et al. Peanut allergy: risk factors, immune mechanisms, and best practices for oral immunotherapy success. Expert Rev Clin Immunol. 2023;19(7):785–95. doi: https://doi.org/10.1080/1744666X.2023.2209318 DOI: https://doi.org/10.1080/1744666X.2023.2209318
  25. Santos AF, Riggioni C, Agache I, Akdis CA, Akdis M, Alvarez-Perea A, et al. EAACI guidelines on the diagnosis of IgE-mediated food allergy. Allergy. 2023 Dec;78(12):3057–76. doi: https://doi.org/10.1111/all.15902 DOI: https://doi.org/10.1111/all.15906
  26. Fernández-Rivas M, Gómez García I, Gonzalo-Fernández A, Fuentes Ferrer M, Dölle-Bierke S, Marco-Martín G, et al. Development and validation of the food allergy severity score. Allergy. 2022 May;77(5):1545–58. doi: https://doi.org/10.1111/all.15165 DOI: https://doi.org/10.1111/all.15165
  27. R Core Team. R: A language and environment for statistical computing. [Internet]. Vienna, Austria; 2022. Available from: https://www.R-project.org
  28. Nachshon L, Schwartz N, Levy MB, Goldberg MR, Epstein-Rigbi N, Katz Y, et al. Factors associated with home epinephrine-treated reactions during peanut and tree-nut oral immunotherapy. Ann Allergy Asthma Immunol. 2023 Mar;130(3):340–346.e5. doi: https://doi.org/10.1016/j.anai.2022.12.001 DOI: https://doi.org/10.1016/j.anai.2022.12.001
  29. Wasserman RL, Hague AR, Pence DM, Sugerman RW, Silvers SK, Rolen JG, et al. Real-World Experience with Peanut Oral Immunotherapy: Lessons Learned From 270 Patients. J Allergy Clin Immunol Pract. 2019 Feb;7(2):418–426.e4. doi: https://doi.org/10.1016/j.jaip.2018.05.023 DOI: https://doi.org/10.1016/j.jaip.2018.05.023
  30. Guarnieri KM, Slack IF, Gadoury-Lévesque V, Eapen AA, Andorf S, Lierl MB. Peanut oral immunotherapy in a pediatric allergy clinic: patient factors associated with clinical outcomes. Ann Allergy Asthma Immunol. 2021 Aug;127(2):214–222.e4. doi: https://doi.org/10.1016/j.anai.2021.04.003 DOI: https://doi.org/10.1016/j.anai.2021.04.003
  31. Blackman AC, Staggers KA, Anagnostou A. Anaphylaxis during Peanut Oral Immunotherapy: looking beyond dose escalation. Pediatr Allergy Immunol. 2022 Dec;33(12):e13888. doi: https://doi.org/10.1111/pai.13888 DOI: https://doi.org/10.1111/pai.13888
  32. Karunakaran D, Chan ES, Zhang Q, Bone JN, Carr S, Kapur S, et al. Risk factors associated with safety of preschool peanut oral immunotherapy. J Allergy Clin Immunol Glob. 2023 Mar;2(2):100094. doi: https://doi.org/10.1016/j.jacig.2023.100094 DOI: https://doi.org/10.1016/j.jacig.2023.100094
  33. Sindher S, Long AJ, Purington N, Chollet M, Slatkin S, Andorf S, et al. Analysis of a Large Standardized Food Challenge Data Set to Determine Predictors of Positive Outcome Across Multiple Allergens. Front Immunol. 2018 Nov;9:2689. doi: https://doi.org/10.3389/fimmu.2018.02689 DOI: https://doi.org/10.3389/fimmu.2018.02689
  34. Nachshon L, Schwartz N, Tsviban L, Levy MB, Goldberg MR, Epstein-Rigby N, et al. Patient Characteristics and Risk Factors for Home Epinephrine-Treated Reactions During Oral Immunotherapy for Food Allergy. J Allergy Clin Immunol Pract. 2021 Jan;9(1):185–192.e3. doi: https://doi.org/10.1016/j.jaip.2020.07.034 DOI: https://doi.org/10.1016/j.jaip.2020.07.034
  35. Virkud YV, Burks AW, Steele PH, Edwards LJ, Berglund JP, Jones SM, et al. Novel baseline predictors of adverse events during oral immunotherapy in children with peanut allergy. J Allergy Clin Immunol. 2017 Mar;139(3):882–888.e5. doi: https://doi.org/10.1016/j.jaci.2016.07.030 DOI: https://doi.org/10.1016/j.jaci.2016.07.030
  36. Vickery BP, Scurlock AM, Kulis M, Steele PH, Kamilaris J, Berglund JP, et al. Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy. J Allergy Clin Immunol. 2014 Feb;133(2):468–75. doi: https://doi.org/10.1016/j.jaci.2013.11.007 DOI: https://doi.org/10.1016/j.jaci.2013.11.007
  37. Lodge CJ, Waidyatillake N, Peters RL, Netting M, Dai X, Burgess J, et al. Efficacy and safety of oral immunotherapy for peanut, cow’s milk, and hen’s egg allergy: A systematic review of randomized controlled trials. Clin Transl Allergy. 2023 Jul;13(7):e12268. doi: https://doi.org/10.1002/clt2.12268 DOI: https://doi.org/10.1002/clt2.12268
  38. Jones SM, Pons L, Roberts JL, Scurlock AM, Perry TT, Kulis M, et al. Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol. 2009 Aug;124(2):292–300. doi: https://doi.org/10.1016/j.jaci.2009.05.022 DOI: https://doi.org/10.1016/j.jaci.2009.05.022
  39. Barshow SM, Kulis MD, Burks AW, Kim EH. Mechanisms of oral immunotherapy. Clin Exp Allergy. 2021 Apr;51(4):527–35. doi: https://doi.org/10.1111/cea.13824 DOI: https://doi.org/10.1111/cea.13824

Most read articles by the same author(s)